| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3876 | Changyu Shen | Beth Israel Deaconess Medical Center | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Aggarwal R, Ruff C T, Virdone S, Perreault S, Kakkar A K, Palazzolo M G, Dorais M, Kayani G, Singer D E, Secemsky E, Piccini J, Tahir U A, Shen C, 7 Yeh R W. (2023). Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. Doi: 10.1161/CIRCULATIONAHA.123.064556 | Boehringer Ingelheim, Daiichi Sankyo | 29 | |
| 3876 | Changyu Shen | Beth Israel Deaconess Medical Center | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Aggarwal, R., Ruff, C., Virdone, S., Perreault, S., Kakkar, A., Palazzolo, M., Dorais, M., Kayani, G., Singer, D., Secemsky, E. and Piccini, J., 2023. Development and validation of the DOAC Score: a novel bleeding risk prediction tool for patients with atrial fibrillation. European Heart Journal, 44(Supplement_2), pp.ehad655-536. Doi: 10.1093/eurheartj/ehad655.536 | Boehringer Ingelheim, Daiichi Sankyo | N/A | N/A |
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192. https://doi.org/10.2215/CJN.0000000000000050 | GlaxoSmithKline, Takeda | 7 | |
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology - Clinical Trials Consortium (CKD-EPI CT) | Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J. and Goicoechea, M., 2023. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, pp.1-10. Doi: 10.1038/s41591-023-02418-0 | GlaxoSmithKline, Takeda | 54 | |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | Vogel LH, Dykun I, Raggi P, Schmermund A, Rassaf T, Mahabadi AA. High- vs. Low-Intensity Statin Therapy and Changes in Coronary Artery Calcification Density after One Year. Journal of Clinical Medicine. 2023; 12(2):476. doi: https://doi.org/10.3390/jcm12020476 | Pfizer | 3 | |
| 4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Feng, S., McLellan, J., Pidduck, N., Roberts, N., Higgins, J.P., Choi, Y., Izu, A., Jit, M., Madhi, S.A., Mulholland, K. and Pollard, A.J., 2023. Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data. EClinicalMedicine, 61. doi: 10.1016/j.eclinm.2023.102073 | Pfizer | 5 | |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi K, Böhringer S, Nam J, et al. POS0181 THE IMPACT OF AUTOANTIBODIES (RF AND ACPA) ON THE EFFICACY OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Annals of the Rheumatic Diseases 2023;82:315-31 6. | AbbVie, Pfizer | N/A | |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V., Ravindranath, V., Arneson, D., Mosenia, A., Butte, A. and Wang, S., 2023. S936 Optimizing Treatment Selection in Crohn's Disease Using Patient-Specific Features: An Individual Participant Data Meta-Analysis of Fifteen Randomized Controlled Trials. Official journal of the American College of Gastroenterology|ACG, 118(10S), pp.S701-S702. Doi: 10.14309/01.ajg.0000953384.20574.a3 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 3 | |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V.A., Ravindranath, V.G., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group. BMC Medical Research Methodology, 23(1), pp.1-12. Doi: 10.1186/s12874-023-02020-5 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | N/A | 0 |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V.A., Ravindranath, V., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Personalizing treatment selection in Crohn's disease: a meta-analysis of individual participant data from fifteen randomized controlled trials. medRxiv, pp.2023-11. Doi: 10.1101/2023.11.10.23291837 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | N/A | |
| 5080 | Joel Skaistis | Beaumont Health | Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker Level | J. Skaistis, J. George, H.C. Diener. Dabigatran Treatment in Embolic Stroke of Undetermined Source and Elevated Biomarkers: the RE-SPECT ESUS Trial. CJC Open (2023). doi : 10.1016/j.cjco.2022.12.013 | Boehringer Ingelheim | N/A | |
| 5209 | Bruce Perkins | University of Toronto | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL | Song, C., Dhaliwal, S., Bapat, P., Scarr, D., Bakhsh, A., Budram, D., Verhoeff, N.J., Weisman, A., Fralick, M., Ivers, N.M. and Cherney, D.Z., 2023. Point-of-care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. Doi: 10.2337/dc23-0840 | Boehringer Ingelheim | 6 | |
| 5276 | Yan Luo | Kyoto University | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | Luo, Y., Chalkou, K., Funada, S., Salanti, G. and Furukawa, T.A., 2023. Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis. JAMA Network Open, 6(6), pp.e2321398-e2321398. doi:10.1001/jamanetworkopen.2023.21398 | UCB | 2 | |
| 5294 | Daniel Caldeira | University of Lisbon/CCUL | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | Caldeira, D., Alves da Silva, P. and Pinto, F.J., 2023. Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY. Stroke. 2023;54:6. https://doi.org/10.1161/STROKEAHA.122.041628 | Boehringer Ingelheim | 3 | |
| 5327, 5985 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Ferreira RJO, Welsing PMJ, Jacobs JWG, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Ann Rheum Dis 2021;80:2, 293-303. doi :10.1136/annrheumdis-2020-217171 | AbbVie, Pfizer, Roche, UCB | 29 | |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Belfiore-Oshan, R., Aggarwal, V., Wilk, J., Pauley, M., Corey, D., Romero, K., Hovinga, C., Martinez, T., Lingineni, K., Yoon, D., Kim, S. and Morales, J., 2023. P146 A clinical trial simulation tool to accelerate trial design in DMD: description of the traphical user interface features and applications. Neuromuscular Disorders, 33, p.S84. Doi: 10.1016/j.nmd.2023.07.081 | CureDuchenne | N/A | |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Jennifer Lees. The impact of age, sex, comorbidity count and race/ethnicity on attrition and screen failure from trials. Kidney Health Symposium 2023, Event held on 24th Feb 2023. (From 34-58 mins) https://ctc.usyd.edu.au/news-events/kidney-health-symposium-2023/ | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | N/A | N/A |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Lees, J.S., Crowther, J., Hanlon, P., Butterly, E., Wild, S., Mair, F.S., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2023. Participant characteristics and exclusion from trials: a meta-analysis of individual participant-level data from phase 3/4 industry-funded trials in chronic medical conditions. medRxiv, pp.2023-04. Doi: 10.1101/2023.04.14.23288549 | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | N/A | N/A |
| 5852 | Marliese Alexander | Peter MacCallum Cancer Centre | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Alexander M, Jachno K, Phillips KA, Seymour JF, Slavin MA, Cheung A, Shen V, Maarouf D, Wolfe R, Lingaratnam S. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice. 2023 Jun 16. doi : 10.1177/10781552231180875 | Roche | 0 | |
| 5924 | Iris Sommer | University Medical Center Groningen | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | d’Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. Published online June 26, 2023. doi:10.1001/jamaneurol.2023.1835 | AbbVie, GlaxoSmithKline, Johnson & Johnson | 16 | |
| 5925 | Min Hwan Kim | Yonsei University College of Medicine | Analysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response | Kim, C.G., Kim, M.H., Kim, J.H. et al. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. Breast Cancer Res 25, 4 (2023). doi : 10.1186/s13058-022-01601-4 | Pfizer | 16 | |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Shin, H., Wang, S.V., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and Najafzadeh, M. Predicting treatment effects of a new-to-market drug in clinical practice based on phase III randomized trial results. Clinical Pharmacology & Therapeutics. Doi: 10.1002/cpt.2983 | Boehringer Ingelheim | 1 | |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Shin, H., Wang, S., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and NajafZadeh, M., 2023. MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. Value in Health, 26(6), p.S285. Doi: 10.1016/j.jval.2023.03.1576 | Boehringer Ingelheim | N/A | |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | Maria A de Winter, Harry R Büller, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Gary E Raskob, Henrik T Sørensen, Frank L J Visseren, Philip S Wells, Jannick A N Dorresteijn, Mathilde Nijkeuter, VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. European Heart Journal, 2023;. ehac776. doi: 10.1093/eurheartj/ehac776 | Boehringer Ingelheim, Daiichi Sankyo | 18 | |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Ferreira, R.J.O., Welsing, P., Jacobs, J.W.G., Gossec, L., Machado, P., Van der Heijde, D. and Da Silva, J.A.P., 2023. OP0189 REMISSION CRITERIA GUIDING IMMUNOSUPPRESSIVE THERAPY IN RA: WHICH IS BEST FITTED FOR THIS PURPOSE?. Doi: 10.1136/annrheumdis-2023-eular.1853 | AbbVie, Pfizer, Roche, UCB | N/A | |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Espinoza, M., Muiquith, M., Lim, M., Zhu, H., Singal, A. G., & Hsiehchen, D. (2023). Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: Post-hoc analysis of IMbrave150. Gastroenterology. doi : 10.1053/j.gastro.2023.02.042 | Roche | 30 | |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Lim, M., Muquith, M., Miramontes, B., Lee, C.J., Espinoza, M., Huang, Y.H. and Hsiehchen, D., 2023. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Hepatology, pp.10-1097. Doi: 10.1097/HEP.0000000000000494 | Roche | 9 | |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Dubbelman, M.A., Vromen, E.M., Tijms, B.M., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2023, July. P1-743 - Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach. In Alzheimer's Association International Conference. ALZ. | Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly | N/A | N/A |
| 6104 | Pratik Sinha | Washington University | Heterogeneous treatment effects in molecular phenotypes of sepsis | Sinha, P., Kerchberger, V.E., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L. and Langelier, C.R., 2023. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. The Lancet Respiratory Medicine. Doi:10.1016/S2213-2600(23)00237-0 | Lilly | 81 | |
| 6475 | Tobias Polak | Erasmus Medical Center | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Polak, T.B., Labrecque, J.A., Groot, C.A. and van Rosmalen, J., 2023. Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access. arXiv preprint. doi: arXiv:2306.01557. | Roche | N/A | |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Yousefi, E., Gewily, M., König, F., Höglinger, G., Hopfner, F., Karlsson, M.O., Ristl, R., Zehetmayer, S. and Posch, M., 2023. Efficiency of Multivariate Tests in Trials in Progressive Supranuclear Palsy. arXiv preprint arXiv:2312.08169. Doi: 10.48550/arXiv.2312.08169 | AbbVie | N/A | |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | Modi, N., Abuhelwa, A.Y., Rowland, A., Menz, B.D., McKinnon, R.A., Sorich, M.J. and Hopkins, A.M., 2023. Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis. Doi: 10.1200/JCO.2023.41.16_suppl.530 | Lilly, Roche, Pfizer | N/A | |
| 6521 | Ethan Alt | University of North Carolina at Chapel Hill | Bayesian probability of success for multivariate generalized linear models | Alt, E. M., Psioda, M. A., & Ibrahim, J. G. (2023). A Bayesian approach to study design and analysis with type I error rate control for response variables of mixed types. Statistics in Medicine. doi: 10.1002/sim.9696 | Biogen | 0 | |
| 6544 | Angela Wu | University of Oxford | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Wu, A.D., Gao, M., Aveyard, P. and Taylor, G., 2023. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders. JAMA Network Open, 6(5), pp.e2316111-e2316111. Doi: 10.1001/jamanetworkopen.2023.16111 | Pfizer | 17 | |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | James R Brorson, Shyam Prabhakaran, S Claiborne Johnston, Mihai Giurcanu. Abstract WMP61: Vulnerable And Stabilized States After Cerebral Ischemic Events: Implications Of Kinetic Modeling In The POINT, SOCRATES, And THALES Trials. Stroke. 2023;54:AWMP61. doi: 10.1161/str.54.suppl_1.WMP61 | AstraZeneca | N/A | |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | Brorson, J.R., Giurcanu, M., Prabhakaran, S. and Johnston, S.C., 2023. Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. Doi: 10.1212/WNL.0000000000207904 | AstraZeneca | 0 | |
| 6594 | Manju Subramanian | Boston Medical Center | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Nayan Sanjiv, Pawarissara Osathanugrah, Steven Ness, Xuejing Chen, Nicole Siegel, Manju L Subramanian. Impact of Race on Treatment of Ranibizumab in Diabetic Macular Edema: A Pooled Analysis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2713. | Roche | N/A | N/A |
| 6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns Disease | C Galts, N Narula, E Wong, W Reinisch. A116 OPTIMIZING CROHN’S DISEASE ENDOSCOPIC SCORING OPERATING CHARACTERISTICS TO ASSIST WITH THE ADVENT OF ARTIFICIAL INTELLIGENCE. Journal of the Canadian Association of Gastroenterology, Volume 6, Issue Supplement_1, March 2023, Page 63. doi: 10.1093/jcag/gwac036.116 | AbbVie | N/A | |
| 6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | Lee JH, Kim S, Oh YM. A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023;18:113-127. doi : 10.2147/COPD.S389502 | GlaxoSmithKline | 1 | |
| 6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | Jang Ho Lee, Sehee Kim, Yeon-Mok Oh. Development of a scoring model for the prediction of the effects of discontinuation or addition of inhaled corticosteroid in chronic obstructive pulmonary disease patients. Volume 28, Issue S1 Supplement: 26th Congress of the Asian Pacific Society of Respirology Above and Beyond, 17 November 2022, Seoul, Korea, February 2023, P45-46 AO07-3. doi: 10.1111/resp.14433#14433-sec-0269 | GlaxoSmithKline | N/A | |
| 6716 | Nigam Shah | Stanford University | Applying machine learning tools to personalize dabigatran treatment decisions | Xu, Y., Bechler, K., Callahan, A., & Shah, N. (2023). Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation. Journal of Biomedical Informatics, 104420. doi :10.1016/j.jbi.2023.104420 | Boehringer Ingelheim | 6 | |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Yongquan (2023). Risk Evaluation for Ischemic Stroke Patients with Non-Valvular Arrythmia by Using Integrated Multistage Machine Learning Predictive Scheme. (PhD thesis. Fu Jen Catholic University). National Digital Libraries of Theses and Dissertations in Taiwan. https://hdl.handle.net/11296/zy9jzs | Boehringer Ingelheim | N/A | N/A |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran. International Journal of Environmental Research and Public Health. 2023; 20(3):2359. doi: 10.3390/ijerph20032359 | Boehringer Ingelheim | 1 | |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Xiao, Z., Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J. and Can, J., 2023. 9P Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. ESMO Open, 8(1). Doi: 10.1016/j.esmoop.2023.101233 | Roche | N/A | N/A |
| 6764 | Camila Olarte Parra | London School of Hygiene and Tropical Medicine | Hypothetical estimand in clinical trials: an application of causal inference and missing data methods | Olarte Parra, C., Daniel, R.M., Wright, D. and Bartlett, J.W., 2023. Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial. arXiv e-prints, pp.arXiv-2308. Doi: 10.48550/arXiv.2308.13085 | AstraZeneca | N/A | |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Rojewski AM, Palmer AM, Baker NL, Toll BA. Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial. Nicotine and Tobacco Research. 2023 Jul 20:ntad126. doi: 10.1093/ntr/ntad126 | Pfizer | 2 | |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Rojewski A, Palmer AM, Baker NL, Toll, BA. SMOKING CESSATION PHARMACOTHERAPY EFFICACY IN COMORBID MEDICAL POPULATIONS: SECONDARY ANALYSIS OF THE EAGLES RANDOMIZED CLINICAL TRIAL. The Society for Research on Nicotine & Tobacco. POS1-12. 2023. | Pfizer | N/A | N/A |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Giulio Francesco Romiti, Marco Proietti, Niccolò Bonini, Wern Yew Ding, Giuseppe Boriani, Menno V. Huisman, Gregory Y.H. Lip. Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry. eClinicalMedicine, Volume 55, 2023, 101757. doi: 10.1016/j.eclinm.2022.101757 | Boehringer Ingelheim | 35 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica B, Romiti GF, Proietti M, Mei DA, Boriani G, Chao TF, Olshansky B, Huisman MV, Lip GY, GLORIA-AF Investigators. Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry. InMayo Clinic Proceedings 2023 Aug 25. doi : 10.1016/j.mayocp.2023.07.013 | Boehringer Ingelheim | 8 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Corica B, Proietti M, Mei DA, Frydenlund J, Bisson A, Boriani G, Olshansky B, Chan YH, Huisman MV, Chao TF. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. eClinicalMedicine. 2023 Aug 25. doi : 10.1016/j.eclinm.2023.102039 | Boehringer Ingelheim | 15 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a Risk Factor for Atrial Fibrillation-Related Stroke. Thromb Haemost. 2023 Oct 23. doi: 10.1055/s-0043-1776394 | Boehringer Ingelheim | 20 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Proietti M, Corica B, Bonini N, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF. J Am Heart Assoc. 2023 Oct 17;12(20):e030565. doi : 10.1161/JAHA.123.030565 | Boehringer Ingelheim | 13 | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Chao, T.F., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2023. Adverse outcomes according to metabolic status in obese and overweight patients with atrial fibrillation: a report from the GLORIA-AF Phase II and III Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-432. Doi: 10.1093/eurheartj/ehad655.432 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti, G.F., Corica, B., Proietti, M., Mei, D.A., Frydenlund, J., Bisson, A., Boriani, G., Olshansky, B., Chan, Y.H., Huisman, M.V. and Chao, T.F., 2023. Oral anticoagulant use and outcomes in Asian patients with atrial fibrillation in the GLORIA-AF Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-433. Doi: 10.1093/eurheartj/ehad655.433 | Boehringer Ingelheim | N/A | |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti, G.F., Proietti, M., Corica, B., Mei, D.A., Frost, F., Bisson, A., Boriani, G., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2023. Impact of chronic obstructive pulmonary disease on the natural history of atrial fibrillation: a report from the GLORIA-AF registry phase II & III. European Heart Journal, 44(Supplement_2), pp.ehad655-573. Doi: 10.1093/eurheartj/ehad655.573 | Boehringer Ingelheim | N/A | |
| 7078 | Alberto Martini | San Raffaele University | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Necchi A, Martini A. PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211. The Journal of Urology. 2023 Apr;209(Supplement 4):page e244. doi: 10.1097/JU.0000000000003240.11 | Roche | N/A | |
| 7078 | Alberto Martini | San Raffaele University | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. The immuneâ€Ârelated adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials. BJU international. doi: 10.1111/bju.16121 | Roche | 3 | |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter S, Porter M, Gibson R, Kimball AB. 423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa. Journal of Investigative Dermatology. 2023 May 1;143(5):S73. https://www.jidonline.org/article/S0022-202X(23)00604-8/pdf | AbbVie | N/A | N/A |
| 7142 | Sara Tedeschi | Brigham and Women's Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Tedeschi S, Hayashi K, Zhang Y, Choi H, Solomon D. Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). | Takeda | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | McDonald CM, Marden JR, Shieh PB, et al. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. Journal of Comparative Effectiveness Research. 2023 Feb:e220190. doi : 10.57264/cer-2022-0190. | CureDuchenne | 4 | |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to event trial endpoints best measured efficacy when seizure counting started during maintenance excluding titration.American Epilepsy Society Annual Meeting. [See Abstracts tab]. Poster 1.285. 2023 | GlaxoSmithKline, Johnson & Johnson, UCB | N/A | N/A |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to prerandomization seizure count demonstrated efficacy of levetiracetam, lacosamide, lamotrigine, and brivaracetam with less placebo exposure. American Epilepsy Society Annual Meeting. [See Abstracts tab]. Poster 1.287. 2023 | GlaxoSmithKline, Johnson & Johnson, UCB | N/A | N/A |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | M. Roulleaux Dugage, M. Tagliamento, T. Gorria, A. Rochand, L. Garcin, S. Oudard, C. Thibault, V.M. Albarran Artahona, J.C. Laguna Montes, I. Nalda Ariza, F.J. Muñoz i Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixido, B. Besse, L. Mezquita, E. Auclin. 1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases. Annals of Oncology (2023) 34 (suppl_2): S755-S851. doi : 10.1016/annonc/annonc1331 | Project Data Sphere, Roche | N/A | N/A |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | M. Roulleaux Dugage, T. Gorria, A. Rochand, L-M. Garcin, S. Oudard, V. Albarrán-Artahona, J.C. Laguna, I. Nalda, F.J. Muñoz-Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixidó, B. Besse, L. Mezquita, E. Auclin. Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC. World Conference on Lung Cancer. (2023). | Project Data Sphere, Roche | N/A | N/A |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | J. Saal, T. Bald, M. Eckstein, D.J. Ralser, M. Ritter, P. Brossart, V. Grünwald, M. Hölzel, J. Ellinger, N. Klümper. A0332 - On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma, European Urology, Volume 83, Supplement 1, 2023, Page S483,ISSN 0302-2838. doi: 10.1016/S0302-2838(23)00381-0 | Roche | N/A | |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology. doi: 10.1001/jamaoncol.2023.1822 | Roche | 13 | |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Eckstein M, Ralser D, Ritter M, Brossart P, Grünwald V, Hölzel M, Ellinger J, Klümper N. (2023). In the phase 2/3 IMmotion150/151 study, the Modified Glasgow Prognostic Score (mGPS) improves the imaging-only prediction of treatment response in patients with metastatic renal cell carcinoma. North Rhine-Westphalian Society for Urology. Doi : 10.3205/23nrwgu20 | Roche | N/A | N/A |
| 7224 | Keiichi Fujiwara | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology | Miyagi, Y., Keiichi Fujiwara, Hisanaga Nomura, Koji Yamamoto, & Robert L Coleman. (2023). Feasibility of New Method for the Prediction of Clinical Trial Results Using Compressive Sensing of Artificial Intelligence. British Journal of Healthcare and Medical Research, 10(1), 237-267. doi : 10.14738/bjhmr.101.14061 | Boehringer Ingelheim, Lilly, Roche | N/A | |
| 7232 | Neil Oxtoby | University College London | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | C. Shand, N.P. Oxtoby. INVESTIGATING TREATMENT EFFECT HETEROGENEITY IN DATA-DRIVEN SUBGROUPS OF TOMMORROW. Journal of Prevention of Alzheimer's Disease. 2023; Abstract P004, pg. S57 | Takeda | N/A | N/A |
| 7321 | Neeraj Narula | Hamilton Health Sciences | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Wong ECL, Merat S, Monaco C, Dulai PS, Jairath V, Marshall JK, Reinisch W, Narula N. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Dig Dis Sci. 2023 Jun;68(6):2635-2646. doi : 10.1007/s10620-023-07956-8 | Johnson & Johnson, Pfizer | 1 | |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Guo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Cancer Communications, 44(2), p.278. Doi: 10.1002/cac2.12512 | Roche | 1 | |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Zhou, Y., Ni, J., Zhu, Z. and Zhang, Z., 2023. Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment. Doi: 10.1200/JCO.2023.41.16_suppl.2032 | Roche | N/A | |
| 7394, 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Manning-Bennett AT, Cervesi J, Bandinelli P-A, Sorich MJ, Hopkins AM. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines. 2023; 11(2):528. doi : 10.3390/biomedicines11020528 | Roche | 1 | |
| 7394, 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Lee X Li, Federico Cappuzzo, Ignacio Matos, Mark A Socinski, Ashley M Hopkins, Michael J Sorich. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The Oncologist, 2023;, oyad043. doi: 10.1093/oncolo/oyad043 | Roche | 8 | |
| 7399 | Yoichi Naito | National Cancer Center Hospital East | Correlation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed. | Naito, Y., Sakamaki, K., Morita, S., Mukohara, T. and Akimoto, T., 2023. 1923P Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma. Annals of Oncology, 34, pp.S1034-S1035. Doi: 10.1016/j.annonc.2023.09.1152 | Lilly | N/A | N/A |
| 7520 | Malathi Ram | Johns Hopkins University | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | Di Stefano, L., Ram, M., Scharfstein, D. O., Li, T., Khanal, P., Baksh, S. N., ... & Freilich, D. A. (2023). Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis. Medicine, 102(23). Doi: 10.1097/MD.0000000000033904 | Bassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota | 2 | |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | Narula, N., Wong, E.C.L., Dulai, P.S. et al. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission. Dig Dis Sci (2023). doi:  10.1007/s10620-023-07825-4 | AbbVie, Takeda | 0 | |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | Wong, E.C., Dulai, P.S., Marshall, J.K., Jairath, V., Reinisch, W. and Narula, N., 2023. Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy. Inflammatory Bowel Diseases, p.izad077. doi: 10.1093/ibd/izad077 | AbbVie, Takeda | 1 | |
| 7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | Abhimanyu M, Gonzalez D A, Stebbins G T & Comella C. 2023. Therapeutic benefit of sensory trick in cervical dystonia. Movement Disorders Clinical Practice. Doi: 10.1002/mdc3.13874 | AbbVie | 1 | |
| 7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | A. Mahajan, D. Gonzalez, G. Stebbins, C. Comella. Quantifying the impact of sensory tricks on the overall severity of cervical dystonia [abstract]. Mov Disord. 2023; 38 (suppl 1) | AbbVie | N/A | N/A |
| 7581 | Rustam Al-Shahi Salman | University of Edinburgh | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | Al-Shahi Salman R, Stephen J, Tierney JF, Lewis SC, Newby DE, Parry-Jones AR, White PM, Connolly SJ, Benavente OR, Dowlatshahi D, Cordonnier C, Viscoli CM, Sheth KN, Kamel H, Veltkamp R, Larsen KT, Hofmeijer J , Kerkhoff H, Schreuder FHBM, Shoamanesh A, Klijn CJM, Van der Worp HB. 2023. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology. doi: 10.1016/S1474-4422(23)00315-0 | Daiichi Sankyo | 14 | |
| 7583, 5932 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | Saifi O, Bachir B, Panoff J, Poortmans P, Zeidan YH. Post-mastectomy Radiation Therapy in HER-2 Positive Breast Cancer after Primary Systemic Therapy: Pooled Analysis of TRYPHAENA and NeoSphere Trials. Radiother Oncol. 2023 Apr 6:109668. doi : 10.1016/j.radonc.2023.109668 | Roche | 3 | |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sudhir Sivakumaran, Yashmin Karten, Nicholas Cullen, Corissa Lau, Eileen Priest, Hazel White, Klaus Romero, Michael Irizarry. Accelerating drug development through precompetitive data sharing and collaboration in the Critical Path for Alzheimer's Disease (CPAD) Consortium. Abstract P0325/#231, p325. | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran, S., Cui, Z., Priest, E., Lau, C., White, H., Irizarry, M.C., Romero, K. and Karten, Y., 2022. Development of Clinical Trial Simulation Tools for Alzheimer's Disease through the Critical Path for Alzheimer's Disease (CPAD) Consortium. Alzheimer's Association International Conference. P4-642. | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. , 2023. PLANNING THE NEXT GENERATION OF ALZHEIMER'S DISEASE CLINICAL TRIALS USING DIVERSE PATIENT-LEVEL DATABASE FROM THE CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) CONSORTIUM. 16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24-27, 2023. PO32. S84. Posters. J Prev Alzheimers Dis 10 (Suppl 1). Doi: 10.14283/jpad.2022.130 | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. . CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) CONSORTIUM: DATA-DRIVEN SOLUTIONS FOR CLINICAL TRIAL DESIGN AND INFORMED DECISION MAKING 16th Clinical Trials on Alzheimer's Disease (CTAD). Boston, MA (USA) October 24-27, 2023. PO33. S85. Posters. J Prev Alzheimers Dis 10 (Suppl 1). Doi: 10.14283/jpad.2022.130 | Lilly | N/A | N/A |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Lupton Brantner, C., Quynh Nguyen, T., Tang, T., Zhao, C., Hong, H. and Stuart, E.A., 2023. Comparing Machine Learning Methods for Estimating Heterogeneous Treatment Effects by Combining Data from Multiple Randomized Controlled Trials. arXiv e-prints, pp.arXiv-2303. Doi: 10.48550/arXiv.2303.16299 | Johnson & Johnson, Lundbeck, Takeda | N/A | |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | A. Salter, S. Lancia, K. Kowalec, K. Fitzgerald, R. A. Marie. O107/355 Prevalence of Comorbidities in Phase III Clinical Trials for Disease-Modifying Therapies in Multiple Sclerosis. MSMilan2023. Oral Presentations. Multiple Sclerosis Journal, vol. 29 no. 3_suppl. Pp 4-136. Page 82. Doi: 10.1177/13524585231196191 | Roche | N/A | |
| 7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Shirley PY, van Middelkoop M, Ferreira ML, Deveza L, Bierma-Zeinstra SM, Venkatesha V, Hunter DJ. The OA Trial Bank: Update of individual patient data meta-analysis of intra-articular glucocorticoids in persons with knee and hip osteoarthritis. Osteoarthritis and Cartilage Open. 2023 Apr 11:100362. doi: 10.1016/j.ocarto.2023.100362 | Sanofi | 2 | |
| 7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Yu, S., Van Middelkoop, M., Ferreira, M., Deveza, L., Bierma-Zeinstra, S.M.A., Venkatesha, V. and Hunter, D., 2023. POS1362 THE OA TRIAL BANK: UPDATE OF INDIVIDUAL PATIENT DATA META-ANALYSIS OF INTRA-ARTICULAR GLUCOCORTICOIDS IN PERSONS WITH KNEE AND HIP OSTEOARTHRITIS. Doi: 10.1136/annrheumdis-2023-eular.1812 | Sanofi | N/A | |
| 7658 | Arman Sabbaghi | Purdue University | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Jiang S., Liu B., Nei L., Sabbaghi A., Abdul Wahab A.H., Qu Y., Lyu T., Zhuang R. Is good enough good enough: A comprehensive evaluation of ICH E9 (R1) Strategies. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. PS5C. 2023. | Sanofi | N/A | NA |
| 7660 | Shirley Yu | University of Sydney | Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysis | Yu SP, van Middelkoop M, Deveza LA, Ferreira ML, Bierma-Zeinstra S, Zhang W, Atchia I, Birrell F, Bhagavath V, Hunter DJ. Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual participant data meta-analysis. Arthritis Care & Research. 2023 Jul 31. doi: 10.1002/acr.25212 | Sanofi | 2 | |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Hopkins, A.M., Modi, N. and Sorich, M.J., 2023. Is there a harmonised standard to oncology trial data provision in data sharing initiatives?. Doi: 10.1200/JCO.2023.41.16_suppl.e13645 | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda | N/A | |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Hopkins AM, Modi ND, Abuhelwa AY, et al. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncol. 2023. doi: 10.1001/jamaoncol.2023.3996 | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda | 7 | |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Kiely, M., Tadount, F., Lo, E., Sadarangani, M., Wei, S.Q., Rafferty, E., Quach, C. and MacDonald, S.E., 2023. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health. Doi: 10.1136/jech-2023-220781 | Sanofi | 4 | |
| 7772 | Neeraj Narula | Hamilton Health Sciences | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Emily C L Wong, BHSc, Parambir S Dulai, MD, Badar Hasan, MD, John K Marshall, MD, MSc, FRCPC, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Combined Histologic and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared to Endoscopic Improvement Alone in Ulcerative Colitis: A Post-hoc Analysis of the VARSITY study. Journal of Crohn's and Colitis, 2023;, jjad033. doi: 10.1093/ecco-jcc/jjad033 | Takeda | 2 | |
| 7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Jonas Saal, Tobias Bald, Markus Eckstein, Manuel Ritter, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper. Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial. JNCI Cancer Spectrum, 2023;, pkad027. doi : 10.1093/jncics/pkad027 | Roche | 6 | |
| 7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Saal, J., Ellinger, J., Ritter, M., Brossart, P., Hölzel, M., Klümper, N. and Bald, T., 2023. Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors. Clinical & Translational Immunology, 12(11), p.e1472. Doi: 10.1002/cti2.1472 | Pfizer, Project Data Sphere, Roche | 3 | |
| 7809 | David James Pinato | Imperial College, London | The predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC) | Claudia A.M. Fulgenzi, Cian Murphy, Antonio D'Alessio, Bernhard Scheiner, Matthias Pinter, Alessio Cortellini, David J. James Pinato. Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study. J Clin Oncol 41, 2023 (suppl 4; abstr 597). doi: 10.1200/JCO.2023.41.3_suppl.597. | Roche | N/A | N/A |
| 7817 | Neeraj Narula | Hamilton Health Sciences | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | Wong, E.C., Gleave, A.L., Marshall, J.K. and Narula, N., Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis. European Journal of Gastroenterology & Hepatology, pp.10-1097. Doi: 10.1097/MEG.0000000000002623 | GlaxoSmithKline | 3 | |
| 7822 | Linbin Lu | The 900th Hospital of PLA | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | Lu, L., Zheng, P., Pan, Y., Huang, S., Shao, E., Huang, Y., Wang, X., Chen, Y., Cuo, G., Yang, H. and Guo, W., 2023. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study. British Journal of Cancer, 129(4), pp.620-625. Doi: 10.1038/s41416-023-02334-7 | Roche | 7 | |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. and Xu, Y., 2023. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Diabetes, 47(7), pp.S209-S210. Doi: 10.1016/j.jcjd.2023.10.390 | GlaxoSmithKline, Sanofi | N/A | N/A |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Cardiology, Volume 39, Issue 10, S252 - S253. doi: 10.1016/j.cjca.2023.06.405 | GlaxoSmithKline, Sanofi | N/A | |
| 7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Debien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Molinelli, C., Branco, D.M., Jacobs, F., Marta, G.N., Lambertini, M. and de Azambuja, E., 2023. 228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial. ESMO Open, 8(1). doi.org/10.1016/j.esmoop.2023.101417 | Roche | N/A | |
| 7858 | Jie Zha | Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patients | Zha, J., Chen, Q., Zhang, W., Jing, H., Ye, J., Yu, H., Yi, S., Li, C., Zheng, Z., Xu, W. and Li, Z., 2023. Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma. Blood, 142(Supplement 1), pp.3048-3048. Doi: 10.1182/blood-2023-182812 | Roche | N/A | |
| 7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Sikkema, B.J., Baart, S.J., Paats, M.S., Smit, E.F., Schols, A.M., Mathijssen, R.H., van Rossum, E.F. and Dingemans, A.C., 2023. 1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453. Annals of Oncology, 34, p.S785. Doi : 10.1016/j.annonc.2023.09.2400 | Roche | N/A | N/A |
| 7875 | Marco Valgimigli | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AÃ…, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051 | Sanofi | 51 | |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Doyle, F. Byrne, D., Boland F. 2023. Do psychometrics matter? The effects of advanced psychometrics on antidepressant randomised trial outcomes. International Society for Affective Disorders. Abstract O-02. pg.47 | GlaxoSmithKline, Lilly, Pfizer, Takeda | N/A | N/A |
| 8294 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Dulai, P.S., Wong, E.C., Johnson, B., Cox, K., Theriault, N., Stefan, M., Eldasher, L.M. and Narula, N., 2023. Su1712 AN ULCERATIVE COLITIS DECISION SUPPORT TOOL PREDICTS DRUG SPECIFIC ENDOSCOPIC REMISSION AND IMPROVES PROVIDER MASTERY IN TREATMENT SELECTION. Gastroenterology, 164(6), pp.S-647. | Pfizer | N/A | N/A |
| 8325 | Xiaodan Tang | Northwestern University | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | Tang, X., Schalet, B.D., Peipert, J.D. and Cella, D., 2023. Does scoring method impact estimation of significant individual changes assessed by patient-reported outcome measures? Comparing Classical Test Theory versus Item Response Theory. Value in Health. doi:10.1016/j.jval.2023.06.002 | Abbvie | 2 | |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Song, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Doi: 10.1159/000531182 | Roche | 10 | |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Song, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. 993P - Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Annals of Oncology (2023) 34 (suppl_2): S594-S618. | Roche | N/A | N/A |
| 8542 | João Sérgio Neves | Faculty of Medicine of University of Porto | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | Neves, J.S., Borges-Canha, M., Vasques-Nóvoa, F., Green, J.B., Leiter, L.A., Granger, C.B., Carvalho, D., Leite-Moreira, A., Hernandez, A.F., Del Prato, S. and McMurray, J.J., 2023. GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with Type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp.517-525. Doi: 10.1016/j.jacc.2023.05.048 | GlaxoSmithKline | 16 | |
| 8555 | Gijsbert Stoet | University of Essex | Effects of exercise on blood glucose levels, food intake and insulin use in adult T1D patients | Stoet, G. and Holt, R.I., 2023. Characteristics of People with Optimally-Managed Type 1 Diabetes. Diabetes Epidemiology and Management, p.100153. doi: 10.1016/j.deman.2023.100153 | Jaeb Center for Health Research Foundation, Inc. | N/A | |
| 8559 | Dag Aarsland | King's College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Xue L, Bocharova M, Young AH, Aarsland D. G18 CLINICAL FACTORS AFFECTING COGNITIVE IMPROVEMENT OF VORTIOXETINE AND DULOXETINE IN ELDERLY PATIENTS WITH MAJOR DEPRESSIVE DISORDER. BAP2023_abstract book, pg A113. | Lundbeck | N/A | N/A |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klü¼mper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology. doi : 10.1016/j.euo.2023.11.005 | Roche | 4 | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Brossart, P., Ellinger, J., Hölzel, M. and Klümper, N., 2023. 1480P Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors. Annals of Oncology, 34, p.S837. Doi: 10.1016/j.annonc.2023.09.2511 | Roche | N/A | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal J., Bald T., Eckstein M., Ralser D., Brossart P., Grünwald V., Hölzel M., Ellinger J. Klümper N. Multi-modal staging in immunotherapy - integrating the on-treatment modi ed Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma. Oncology Research and Treatment. 2023. (suppl 5):1-354 Pg. 77 Abstract V511. Doi: 10.1159/000533576 | Roche | 0 | |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Ellinger, J., Ritter, M., Brossart, P., Hölzel, M., Klümper, N. and Bald, T., 2023. Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors. Clinical & Translational Immunology, 12(11), p.e1472. Doi: 10.1002/cti2.1472 | Roche | 3 | |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Alfehaid L, Alkhezi O, Buckley L, Libby P, Desai A, Tawifk Y, Shah A. COLCHICINE, DRUG-DRUG INTERACTIONS AND GASTROINTESTINAL ADVERSE EFFECTS. American College of Clinical Pharmacy. Session IV. 2023. | Montreal Heart Institute | N/A | N/A |
Center for Global Research Data